Valitor to Present on its Drug Candidate with Twice-Yearly Dosing for Wet AMD at the American Academy of Ophthalmology's Eyecelerator Conference and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

BERKELEY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its president and chief scientific officer, Wesley Jackson, Ph.D., will present a company and program overview at the Eyecelerator Conference hosted by the American Academy of Ophthalmology on Friday, May 2 in Park City, Utah. The presentation will be part of the Retina – TKI and Drug Delivery Showcase at 1:52 p.m. MT. Eyecelerator Key Highlights: Valito ...